Cite this article:
Bellamakondi, Rao, OS, Varma and P (2016). Liv52 a Poly Herbal Formulation Ameliorates Inflammation and Metabolic Overload Induced Fibrosis by Retarding the Stellate Cell Activation - An In vitro Evaluation. Journal of Ravishankar University (Part-B: Science), 29(1), pp.77.https://doi.org/
OP-C05
Liv52 a Poly
Herbal Formulation Ameliorates Inflammation and Metabolic Overload Induced
Fibrosis by Retarding the Stellate Cell Activation - An In vitro Evaluation
Pavan Kumar Bellamakondi',
Raghavendra P Rao, Thiyagarajan OS, Sandeep Ravi Varma and Rangesh P
The Himalaya Drug Company,
Research and Development Centre, Makali, Bangalore 562 162
Corresponding author email: pawan.kb@himalayweliness.com
[Received
6 January 2016, accepted 14 January 2016]
Abstract: Liver
fibrosis results due to excessive accumulation of extracellular matrix proteins
including collagen. It is a complex process involving various cell types of
liver including hepatocytes, several immune cell types and stellate cells.
Current strategies for the treatment of liver fibrosis have shifted from single
target approach to multi target approach and plant extracts contain several
bioactive molecules which act on multiple pathways. In view of this, Liv.52 is
one of the polyherbal formulations known worldwide for its beneficial effects
against liver ailments. In the present study, we have evaluated the molecular
mechanism of action of this polyherbal formula in an in vitro set up that
captures metabolic overload, inflammation and stellate cell activation. HepG2
(Human, liver hepatoma) cells were exposed to palmitate and CCL, (carbon
tetrachloride) for 24 hours to induce lipotoxic inflammation following which
the conditioned media was used to induce stellate cell activation in HHSTEC
(Human Hepatic Stellate) cell line. The effect of Liv52 on lipotoxicity and
inflammation induced stellate cell activation was evaluated. Liv.52 showed
14.8522.47% protection against lipotoxicity and attenuated the expression of
key markers of stellate cell activation viz. ACTA2 and Desmin and significantly
reduced the levels of ECM (extra cellular matrix) proteins accumulation as
measured by expression levels of lumican and cellular collagen content. Thus,
the results indicate that Liv.52 efficiently counters the effects of metabolic
overload and inflammation induced liver injury and halts the stellate cell
activation, a central event in the process of progression of liver fibrosis.
Keywords: Liver fibrosis, Metabolic overload, Extra cellular proteins